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We forecast UK pharmaceutical time series before and after the time of patent expiry. This is a critical point in the respective lifecycle as a generic form of the product is introduced to the market, while the branded form is still available for prescription. Forecasting the number of dispensed units of branded and generic forms of pharmaceuticals is increasingly important due to their huge market value and the limited number of new ‘blockbuster’ branded drugs, as well as the imposed cost to national healthcare systems like the NHS. In this paper, eleven methods are used to forecast drug time series including Diffusion Models (Bass model & RPDM), ARIMA, Exponential smoothing (Simple and Holt), naive and regression methods. ARIMA and Holt produce accurate short term (annual) forecasts for branded and generic drugs respectively, while for the more strategic horizons of 2-5 year ahead, Naive with drift provides the most accurate forecasts.










Marketing professionals and academics alike should strive to become more socially aware (Andreasen, 1978) and to that end forecasting plays a major role in increasing marketing relevance, as it’s included in more than 98% of companies’ marketing plans; and should be taught in business schools as a vital marketing tool (Armstrong, Brodie, & McIntyre, 1987). Despite its importance, managers do not appear to use forecasting effectively. This was evident when a survey of marketing managers found that self-reported forecast accuracy did not exceed 47% for new category entrants, and 40% for products that were new to the world (Kahn, 2002).
The introduction of new products in a given period changes the existing industry, as it adapts so as to include them (Darroch & Miles, 2011), and affects how forecasting managers perform. Many companies cite forecasting of genuinely new products as one of the most difficult forecasting problems they face, considering that new product forecasting is a leap into the unknown with little or no historical information available, which can require substantial time from the sales forecasting team, hurt its credibility through poor forecasting accuracy, and reduce its morale (Mentzer and Moon, 2005).


In this study we forecast pharmaceutical life cycles before and after the time of patent expiry. This is a critical point in the respective lifecycle as for the first time a generic form of the product could be introduced to the market, while the branded form is still available for prescription. From an economics and finance point of view, assessing the number of dispensed units of branded and generic forms of pharmaceuticals is increasingly important due to their huge market value and the limited number of new ‘blockbuster’ branded drugs. As a result, pharmaceutical companies make every effort to extend the commercial life of their branded products and forecast their sales in the future. On the other hand public health institutes seek insights for effective governance as the use of a branded drug, when a generic form is available is quite costly.






This study contributes to the existing body of literature by applying forecasting methods to the life cycles of pharmaceutical drugs and assessing the number of dispensed units. Previous studies by Cox (1967) and Easingwood (1987) modelled pharmaceutical life cycles but did not incorporate the forecasting element. This research aims to update and extend the existing with a specific focus on the life cycles of branded drugs that decline as soon as generic alternatives enter the marketplace.
In this context, successful forecasting and assessment of the number of dispensed units enable marketing managers to implement strategies that allow them to advantageously modify a product’s life cycle, to increase sales, profitability and decrease losses. They can use such information if they know how products are likely to perform at the yearly level in order to construct annual budgets and respective plans. They can also employ proactive strategies to slow down the decline of the drug or look at introducing alternatives.
Many models are used to predict new product sales, but they were limited to consumer goods and did not address pharmaceuticals. Models were proposed that specifically consider pharmaceutical drugs (Lilien, Rao, & Kalish, 1981), which were then changed and its predictability were tested using pharmaceutical data (Rao & Yamada, 1988). The traditional Bass (1969) model, like other methods used to predict consumer goods, may not be suitable for pharmaceutical products. The application and predictability of diffusion models have received limited empirical testing with mixed results; however, complicated forecasting techniques do not always generate the most accurate results, and in some situations, simpler approaches can be more effective (Makridakis and Hibon, 2000). 
3. The Pharmaceutical Market

The pharmaceutical industry is one of the UK’s largest manufacturing sectors. In 2009, it was ranked 8th in the world, with an income of £7 billion. The UK pharmaceutical market is equally lively, with drugs continually entering the market. This created a particular interest in studying the interactions between branded and generic versions of these drugs, as they can cause the greatest loss of revenue to pharmaceutical companies (ABPI, 2011).On the other hand, healthcare agencies and regulating bodies may wish to make life-saving drugs available to the total population at an affordable through some form of regulation (Verniers, Stremersch and Croux, 2011).
Two types of drugs tend to be available in a given market; branded drugs and their generic equivalents that can be both owned by the same pharmaceutical company, although more often than not, they are owned by competing companies. A branded drug is generally protected by a patent that prevents the introduction of cheaper alternatives until its patent expires. A patent is granted when the molecule is initially developed and lasts for approximately 20 years. This means that the drug is protected through pre-clinical and clinical trials, the approval process and finally introduction to the market. This introduction can occur 10-15 years after the drug was first developed; therefore, the amount of time the drug is protected in the marketplace is limited. Generic equivalents are able to enter the market upon patent expiry quickly, as they are not subject to the same lengthy development and approval process as the branded drug. While being equivalent to the branded drugs in terms of their bio-activity, generics can differ from the brands in their colour, shape, and packaging as well as price (ABPI, 2011).

When a generic drug enters the market, the number of prescriptions written for the branded version declines, while the number of generic prescriptions increases at the same rate (or even faster). It was found that the persuasive role associated with detailing is responsible for GPs (General Practitioners) switching between brands that contain the same active ingredient, therefore, detailing should not be limited as it is likely to limit the rate of learning for GPs (Ching and Ishihara, 2012). On the contrary, detailing is most effective as an acquisition tool (Montoya, Netzer & Jedidi, 2010). Detailing should be targeted and combined with journal advertising in order to have a positive influence on an individual GP's adoption of a new drug (Liu and Gupta, 2011).

In addition, GPs have a tendency to switch to cheaper generic alternatives when they become available (Frank & Salkever, 1997); (Kvesic, 2008) which can even occur before the patent has expired. Moreover, generic entry not only leads to the expected decrease in the prescription of the branded molecule bioequivalent to the generics, but also unexpectedly benefits other non-bioequivalent branded drugs as detail-sensitive physicians switched from the contested molecule to other branded alternatives(Gonzalez, Sismeiro, Dutta, & Stern, 2008). However, contrary evidence suggests that some GPs do not switch immediately, lending support to the idea that generics are not perfect substitutes for the branded versions (Ferrándiz, 1999). When a GP prescribes a drug in the UK, the pharmacist dispenses what is written on the prescription. The only exception to this rule occurs when a patent still exists; in this case, if the GP prescribes the patented drug using its generic name, the branded version will be dispensed (Stern, 1994, 2002).

3.1 Pharmaceutical life cycles

The study of brand life cycles has a long history dating back to Polli and Cook (1969) and more recently, Bauer& Fischer (2000). However, there is limited research on forecasting life cycles of branded pharmaceuticals that are followed by the life cycles of their generic alternatives when they enter the market (Levitt, 1965).

The present study aims to develop this area of research specifically by considering the interaction between the life cycles of branded and generic pharmaceuticals, as these cycles can be extremely unstable, with seasonal variations and trends occurring within the UK data. Easingwood (1987) modelled product life cycles using a Diffusion Model but stopped short of the forecasting phase, while Cox (1967) produced six polynomial variations of the pharmaceutical life cycle, of which only Type 1 is the one life cycle variation described by Cox (1967) that follows the normal parabola curve of the product life cycle. 

Therefore, if we are able to forecast the number of prescriptions for a given medicine ultimately we can decide whether we want to allow the drug to decline at its current rate or introduce measures to slow that decline, or perhaps do both while we innovate and create a new variation of the same product. This allows the company time to develop alternative strategies so that a limited amount of revenue is lost. With the lack of applying any forecasting techniques to such area, this left a gap that this study addresses.

Product life cycle has four key stages—introduction, growth, maturity, and decline—all of which can be modelled and forecasted. During the introduction stage, the uptake of the product is generally low, with most marketing costs incurred during this period (Masterson & Pickton, 2014). Once the product enters the growth phase, its sales begin to increase rapidly, and repeat purchasing starts. The end of this phase sees the introduction of imitation products rivalling the current one. These imitators are often cheaper and better than the original product. In the maturity phase, the sales of the product peak and begin to level off. The brands remaining in the market at this stage compete for market share (Bayus, 1994). As products mature, the number of technological advances and innovations, which may have taken place in the introduction and growth phases, declines, while the final phase is mainly the decline and withdrawal phase, when the sales and profits start to fall(Agarwal & Gort, 2002).Managers are becoming increasingly aware that they must understand sales patterns and change their strategies to address these patterns (Golder & Tellis, 2004).
3.2 Reasons for peak sales

Demand for a new drug comes from new adoptions and repeat prescriptions written by GPs, as sales for most drugs exhibit a peak before tailing off. This holds for the branded drug and its generic equivalents when they enter the market (Fischer, Leeflang, & Verhoef, 2010). Fischer et al. (2010) posit a number of reasons that products, especially pharmaceuticals, exhibit sales peaks. First, sales appear to be driven more by new prescribers than repeat prescriptions; due to the lack of switching behaviour among GPs when a drug that works for a patient is identified, however this really depends on the therapeutic area. 

Second, pharmaceutical companies tend to focus their marketing efforts in the first two years following product launch (Osinga, Leeflang, & Wieringa, 2010), causing an increase in the number of prescriptions written by GPs. However, sales can be reduced and may even decline when the pharmaceutical companies’ marketing efforts begin to tail off (Osinga et al. 2010). Fischer et al. (2010) also note that a limit exists to the number of final consumers of the drug because each drug is only relevant for patients in need of a specific treatment for a specific problem, however this also depends on the therapeutic area. Finally, when a patent on the branded drug expires and generic alternatives enter the market, competition increases and branded drug sales generally decline (Aronsson, Bergman & Rudholm, 2001), (Fischer et al., 2010), (Jain and Conley, 2014).






3.3 The critical forecasting horizon for the pharmaceutical industry 






4. The Data: prescriptions and dispenses in the U.K.

The data are part of the JIGSAW database, a commercially operated panel of GPs and was donated by Synovate for the purposes of academic research. The database was established by ISIS research in 1985. The time series associated with the current research are taken from a much larger database that contains 2,570,000 prescription records from 1,506 GPs all over the United Kingdom. The time series run from 1987-2008. From this database, the most-prescribed chemical substances were selected and that resulted in seven substances that exceeded the ad-hoc threshold of 10,000 total prescriptions. Those chemical substances were initially circulated as branded drugs, but once the patents of these expired both a branded and a generic version of each substance were available in the market. Those seven substances that were selected had over 10,000 prescriptions recorded (in either their branded or generic forms) between 1987 and 2008 (Table 1).
All these drugs exhibited a branded-generic crossover; sales of the branded version first increased before reaching its peak, and then began to decline. Upon patent expiry, the number of generic prescriptions increased, peaked and then began to decline as new prescription medicines are always being released. These drugs are definitely cheaper to produce and may (or not) have fewer side effects for the patient. If this is the case then GP’s may switch the patient to the newer medicine. This is the primary life-cycle pattern exhibited by the branded and generic versions of the same pharmaceutical drug (Kvesic, 2008).

Table 1. Basic information on the seven most-prescribed substances in the database (Source: MPA Services, Espacenet and Patent Archives)

4.1 Prescribed versus dispensed







However, after patent expiry, the generic version would have to be dispensed in that case instead, while the branded version would only be dispensed if a GP prescribed it explicitly. Figure. 1 illustrates an example (generic: Ranitidine) that depicts the differences between the drugs that were initially prescribed by the GPs and the drugs that were actually dispensed by the pharmacists.


Figure 1. The differences between GPs’ prescriptions and the pharmaceuticals actually dispensed
We point out to the reader the differences between the number of prescriptions written and dispensed for Zantac/Ranitidine. The number of dispensed prescriptions for Zantac is higher because although some GPs prescribed Ranitidine, the prescriptions were dispensed as Zantac until 1997, when the patent expired.
5.  Forecasting models

In this study, the Operation Research (OR) forecasting paradigm is adopted and applied to the pharmaceutical industry in the UK. The aforementioned paradigm  promotes competition between different forecasting techniques via a holdout period on which various forecasting horizons are simultaneously and in a rolling fashion evaluated, in order to determine the most accurate ones.





Diffusion Models have been employed in several areas of marketing; including consumer behaviour, marketing management and marketing science research. The generalised Bass model is popular in both normative and descriptive applications (Fruchter and Van den Bulte, 2011). Researchers have contributed to the diffusion theory by developing forecasting techniques associated with Diffusion Models, which were initially developed by Frank Bass (1969).
The Bass Diffusion Model describes how new products are adopted as an interaction between users and potential users. This theory of adoption and diffusion was first developed conceptually by Rogers (1962) as he stated that individuals can decide to adopt a product independently of other influences. These people are generally known as the innovators of a product. 

The model developed by Bass (1969) implies exponential growth followed by a peak and then a decline. The model provides good predictions for the products to which it was applied to and, according to Bass, it is useful in providing a basic rationale for long-range forecasting (Bass, 1969). Since its inception, there have been many extensions of the original Bass Diffusion Model. 
[For more details on the technical aspects of the Bass model the reader may visit Appendix A1]


Repeat Purchase Diffusion Model (RPDM)
A three-step methodology was proposed by Lilien et al. (1981)to predict the sales of new drugs when they enter the market when little or no prior data are available. The steps proposed were:
1.	To use historical time series data associated with prescription drug introductions to develop sales models as a function of the total number of GPs in the target market and a number of other marketing variables, as GPs tend to repeat-prescribe new drugs, the model represents a repeat purchase diffusion process.
2.	A model is then produced to forecast the sales of the new drug prior to entering the market. It suggested that this model is parameterised on a drug that the management deem “similar” to the new drug being introduced to the market.
3.	The final step aims to use early sales data gathered to update the model to make it more accurate using Bayesian regression. This approach is valid when no prior data are available, but if sales data are available, the RPDM can be used accurately to produce one-step-ahead forecasts (Rao & Yamada, 1988). This model provides the best fit for pharmaceutical data when the decay factor is removed.




For the sake of comparison to diffusion models , three simple regression models have been tested:
	Regression over t 
	Introducing a lag with a Regression over t-1
	Robust Regression with the following variables been employed as explanatory: number of prescriptions, number of GP's and Year
Robust regression is an alternative to least squares regression when data is potentially including outliers. 

5.3 Other popular forecasting models

Consistent with the OR paradigm, a number of basic benchmarks as well as popular models in forecasting competitions (Makridakis and Hibon, 2000) have also been included in the competition and implemented and automatically initialised and optimised  in STATA 11, including:
	the Naïve Model
	 Moving Average of 3 periods, a common choice for annual data especially with limited history available
	Simple Exponential Smoothing 
	Holt Exponential Smoothing
	ARIMA 
There was obviously no need to include seasonal methods or apply a classical seasonal decomposition to the aforementioned methods/models as the dataset we analysed included yearly data.

6.  Empirical Results & Discussion


With twenty-one years of data available for each drug, the first data points are used to estimate the model; however, in some cases, there are fewer data points due to the patent expiration date. This is a direct result of the patent expiration of a high number of branded pharmaceuticals that took place in the 1990’s, which meant that once the 5 period hold-out was included there would not be enough data points available to produce accurate forecast comparisons.

The models were estimated using statistical software STATA and a Non-Linear Approach was conducted for the RPDM and Bass Diffusion Models. Table 2 below shows the total number of annual data points available for each drug time series and the number of observations available for forecasting. Three of the seven pairs (branded and generic versions) had a very limited history with for the generic alternative. This is because for Sertraline, Meloxicam and Ramipril, the generic alternatives f had been released quite close to the final year in the database with 3, 5 and 4 annual observations respectively. As a result, there were very few data point to initialise any forecasting model, thus these three generics were excluded from the forecasting evaluation.

The chosen models were applied to the data describing the dispensed pharmaceuticals rather than the prescribed ones.  The first five data points of the time series were used to forecast the 6th, the 6th was used to produce the 7th, and so on.

Table 2. Data points available for forecasting

In a typical forecasting competition setup, where we compare the performance of various forecasting models/methods against each other, we are primarily interested in three forecasts’ characteristics:
•	Bias, as if there is a systematic tendency to over/under-forecast the actual values
•	Accuracy, in terms of how close the provided forecasts are to the actual values
•	Uncertainty, in terms of how big is the average deviation of the provided forecasts from the mean forecast.

Standard proxies for the aforementioned characteristics are the following metrics: Mean Error (ME) for the bias, Mean Absolute Error (MAE) for the accuracy and Mean Squared Error (MSE) for the uncertainty (Makridakis and Hibon, 2000). A more intuitively appealing choice for the evaluation of the forecasting accuracy is to use a relative metric instead i.e. the Relative Absolute Error (RAE) which is just the ratio of the MAE of an evaluated method divided by the MAE of a benchmark method – in this instance the Naïve method for one-year ahead forecast. The reason for the popularity of this specific metric is that it is very easy to interpret; if it is less than the value of the benchmarked method then the evaluated method forecasts better than the benchmark and vice versa.


















6.1 Forecasting with the Diffusion models 















Table 3. Diffusion models - model Fitting

The R2 values for both the RPDM and the Bass (1969) Diffusion Model provide significant results for the eleven pharmaceuticals that were forecasted. The lowest R2 in the RPDM was for Tritace (0.70); in the Bass model, it was for Atenolol (0.67). Two illustrative examples of forecasts from the models are presented in Figures 2 and 3 respectively.

Figure 2. Forecasts from the Bass Model.






6.2 Forecasting Branded Pharmaceuticals

Branded pharmaceuticals are expected to follow the classical product lifecycle curve until this is interrupted by the patent expiry when then alternative products become available in the market and where then a very steep descent in demand is expected. As such there is no preconception of what kind of models might be more appropriate given that is not a-priory known the exact phase of the lifecycle when the patent is about to expire. The results of our evaluation are presented in tables 4, 5 and 6.
	Naïve Methods	Exponential Smoothing	ARIMA	Diffusion Models	Regression Models





Table 4. Short-term forecasting horizon: 1 year ahead. Forecasting Bias, Accuracy and Variance (ME, RAE, MSE) of Branded Drugs

Table 4 presents the forecasting errors for the branded drugs - on average across the seven drugs and respective time series, for each of the models used in the study. The error results in Tables 4 clearly shows that the ARIMA model was the most accurate for forecasting the time series of branded drugs for the immediate one-year ahead forecasting horizon.  The results remain the same across all three performance metrics of  bias, accuracy and variance (ME, RAE, MSE).

	Naïve Methods	Exponential Smoothing	ARIMA	Diffusion Models	Regression Models





Table 5. Mid-term forecasting horizon: 2–3 year ahead. Forecasting Bias, Accuracy and Variance (ME, RAE, MSE) of Branded Drugs

Table 5 presents the average forecasting errors for the branded drugs for each of the models used in the study when forecasting two and three years ahead. Table 5 shows that the model with the lowest error was the ARIMA with the error results for the Robust Regression coming in a close second. The results remain the same across all three performance metrics of  bias, accuracy and variance (ME, RAE, MSE).

	Naïve Methods	Exponential Smoothing	ARIMA	Diffusion Models	Regression Models





Table 6. Long-term forecasting horizon 4–5 year ahead: Forecasting Bias, Accuracy and Variance (ME, RAE, MSE) of Branded Drugs








6.4 Forecasting Generic Pharmaceuticals

Generic pharmaceuticals are expected to follow a different patter than the respective branded ones. This should entail a rapid growth right after the patent expiry of the branded alternative and as such trended models might have an advantage in this forecasting evaluation. Results are presented in tables 7-9
  	Naïve Methods	Exponential Smoothing	ARIMA	Diffusion Models	Regression Models






Table 7. Short-term forecasting horizon: 1 year ahead. Forecasting Bias, Accuracy and Variance (ME, RAE, MSE) of Generic Drugs

Table 7 presents the average forecasting error across the seven generic drugs for one-year ahead. The forecasting error results presented in Table 7 clearly show that Holt  Exponential Smoothing was the most accurate method for forecasting on average the respective time series of generic drugs. The results remain the same across all three performance metrics of  bias, accuracy and variance (ME, RAE, MSE).

	Naïve Methods	Exponential Smoothing	ARIMA	Diffusion Models	Regression Models





Table 8. Mid-term forecasting horizon: 2–3 year ahead. Forecasting Bias, Accuracy and Variance (ME, RAE, MSE) of Generic Drugs

Table 8 presents the forecasting errors for the mid-term forecasting horizon of 2-3 years ahead for the generic drugs over the same forecasting horizon and clearly shows that the most accurate forecasting model is again that of Holt  Exponential Smoothing. The results remain the same across all three performance metrics of  bias, accuracy and variance (ME, RAE, MSE).


	Naïve Methods	Exponential Smoothing	ARIMA	Diffusion Models	Regression Models






Table 9. Long-term forecasting horizon: 4–5 year ahead. Forecasting Bias, Accuracy and Variance (ME, RAE, MSE) of Generic Drugs









7. On the (empirical) quest for an optimal drift 

Given the success of trended models in the empirical investigation presented in the previous section especially for the generic drugs, we would like to investigate this aspect further. One way is to try find an optimal trend via adding gradually one the Naive model. There is also some scope for doing the same for branded drugs as trended models could capture the growth and the steep decline phase of the respective time series. 

These trended extrapolation models tend to capture the medium to long-term trends, however these did not usually produce any better forecasts than the Naïve model; the same stands for the trended version of Exponential smoothing models like Holt Exponential Smoothing and the Theta model (Makridakis and Hibon, 2000, Assimakopoulos and Nikolopoulos, 2000).

Our next step was to add a term (called a drift), which is the difference of the last two known actual observations, in order to capture the very- short-term trend in the data. Given the dominant success of the Naive model in our empirical competition, it was decided to add a drift only in this model, thus employing the Naive with drift model, where the forecasting equation is as follows:
Ft+1=Yt+dt,    where the drift is dt=Yt-Yt-1(7)

Or if we do not want to use the full drift (and instead just a portion of it) then our model becomes:
	Ft+1=Yt+α dt,    dt=Yt-Yt-1, 0<α<1 (8)

Tables 10 and 11 below show the forecasting performance of the Naïve with drift model for forecasting horizon 1, where α is introduced in 10% increments:

Table 10. Forecasting Horizon 1, Naïve + Drift, Branded Drugs
Table 10 shows the ME of the branded pharmaceuticals decreases as the percentage of drift increases, while the RAE and MSE on the other hand increase as the percentage of drift increases. These results suggest that for branded pharmaceutical life cycles the most appropriate forecasting method is Naïve+20% drift. This drift has been selected as it has the lowest ME and MSE, while the RAE is 0.98 which shows the method has a high level of forecasting accuracy.


Table 11. Forecasting Horizon 1, Naïve + Drift, Generic Drugs
Table 11 also shows that the ME of the generic pharmaceuticals declines as the percentage of drift increases. Both the RAE and MSE decline as the drift increases to 70%. After this point the RAE and MSE start to increase again. This shows that the best forecasting method for the generic pharmaceutical life cycle is Naïve+70% drift. These forecast results show that branded and generic pharmaceutical life cycles both need different level of drift so as to forecast them as accurately as possible. If this optimum drift needs to be visualised, it may graph the plots of how the error (RAE) changes in terms of the selected α parameter, as in Figure 4.

Figure 4. Level of Drift for Forecasting Horizon 1 (in terms of RAE) for Branded and Generic Pharmaceutical Life Cycles

Tables 12 and 13 show the forecasting performance of the Naïve with drift model for forecasting horizon of 2-3 years ahead.

Table 12. Forecasting 2-3 years ahead: Naïve + Drift, Branded Drugs

Table 13. Forecasting 2-3 years ahead:Naïve+Drift, Generic Drugs

Tables 12 and 13 show that the ME, RAE and MSE of the branded and generic pharmaceuticals decrease as the percentage of drift increases. The results suggest the most appropriate forecasting method for a 2-3 year ahead forecast for a branded drug is Naïve+100% drift. This drift has been selected because it has the lowest ME, MSE and RAE.  The same method also holds as the most accurate for the generic drugs at a 2-3 year ahead forecast horizon.  The results show at the 2-3 year ahead level both the branded and generic pharmaceuticals can use the same forecasting method. Figure 5 provides a visualisation of the optimum level of drift plotted against the RAE. 

Figure 5. Level of Drift for Forecasting 2-3 years ahead (in terms of RAE) for Branded and Generic Pharmaceutical Life Cycles

Tables 14 and 15 show the forecasting performance of the Naïve with drift model for forecasting horizons of 4-5 years ahead.

Table 14. Forecasting 4-5 years ahead: Naïve + Drift, Branded Drugs


Table 15. Forecasting 4-5 years ahead: Naïve+Drift, Generic Drugs

Tables 14 shows that the ME, RAE and MSE of the branded pharmaceuticals decrease as the percentage of drift increases. The results suggest the most appropriate forecasting method for a 4-5 year ahead forecast for a branded drug is Naïve+100% drift. This drift has been selected because it has the lowest ME, MSE and RAE.  Table 15 shows the same method also holds as the most accurate for the generic drugs at a 3 year ahead forecast horizon. The results show at the 4-5 year ahead level both the branded and generic pharmaceuticals can use the same forecasting method. Figure 6 provides a visualisation of the optimum level of drift plotted against the RAE. 

Figure 6. Level of Drift for Forecasting 4-5 years ahead (in terms of RAE) for Branded and Generic Pharmaceutical Life Cycles





8. More thoughts, conclusions and further research

This paper provided the first to our knowledge empirical forecasting competition of pharmaceutical time series, especially given the separate treatment of branded and generic  drug respective series.

To that end diffusion models would be a natural choice, as the RPDM previously used - in a limited evaluation however - by Rao and Yamada (1988). The results of the comparisons between RPDM and the Bass model show that the pharmaceutical life cycle can be modelled effectively using both models, however when it comes to out-of-sample forecasting, the performance is rather mediocre.

One could argue that this latter result is to some extent expected as the Bass model is aimed at modelling adoption, not sales or related measures. In the situation where each new adopter would buy once, the number of new adopters would equal sales. Also, if every new adopter would keep on purchasing at a fixed rate, one could use the cumulative number of adopters to proxy sales. In the setting studied here neither situation seems to apply: most physicians prescribe more than just once, and the steep decline in brand sales is inconsistent with a fixed repeat purchase rate combined with the cumulative number of adopters. The RPDM model does not alleviate the problems described above, since it does not explicitly allow for a steep decline after patent expiration.


Thus there was a need to look at different avenues for picking up more appropriate forecasting models for 'that' type of data - pharmaceutical, which brings the discussion back to the holy grail of forecasting: a 'horses for courses' approach (Petropoulos et al. 2014).

Branded pharmaceuticals are expected to follow the classical product lifecycle curve (introduction - growth - maturity - decline) until this is interrupted by the patent expiry, when then alternative products become available in the market in the form of generics. As such, there is no preconception of what kind of models might be more appropriate given that is not a-priory known the exact phase of the lifecycle that will be prevailing when the patent expires. 

The results support this intuition as a quite adaptive method - ARIMA, that allows for different models to be used for each series (within the generic Box-Jenkins framework though), manages to provide the most accurate, less biased and less volatile forecasts on average across the seven series for the one-year ahead. For longer horizons up to five years ahead naive with various levels of drift does the job.
 
Generic pharmaceuticals on the other hand are expected to rapidly grow right after the patent expiry of the branded alternative, and as such trended models might have an advantage in this forecasting evaluation. This expectation is met in our evaluation as for one-year ahead a trended model - Holt Exponential smoothing provides the best forecasts across all three dimension of accuracy, bias and uncertainty. Yet again, for longer horizons up to five years ahead naive with various levels of drift is the one method that provides the best results.

Overall given the nature of  both the branded and generic drug time series, and the steep growth and decline phases of the branded ones as well as the steep increase of the newly introduced generic ones, it is not surprising that there is always a certain level of drift that could provide superior forecasting performance for the longer forecasting horizons; it is not however always the same level of drift though, and as such yet again ... one size does not fit all!

Further investigation is needed to determine whether pharmaceutical drugs that exhibit other life-cycle formats can also be forecasted effectively with similar methods and models. The branded and generic crossover points of many drugs can vary from those in the current study. The drugs studied here tend to adhere to the main pattern of an increase in branded sales followed by a decline, then a rise in generic sales followed by an eventual decline. However, not all drugs exhibit this pattern. 

A comparison of the different stages of the pharmaceutical life cycles may also be an appropriate extension to this study, as the RPDM model exhibited a higher level of forecasting accuracy when considering only the maturity stage of the life cycle compared to the period of the drug’s decline. Another suggestion is to forecast data on a 10 year ahead level. This might not be viable for the UK market, however, it would be more appealing for the global market.
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